CLINICAL_TRIALS
trial_result
· 2019-10-30
Clinical Trial Update: A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions [Phase 4]
Summary
A Phase 4 bioavailability study comparing two erlotinib 150 mg formulations under fasting conditions has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Quadras Scientific Solutions | Conditions: Lung Cancer | Phase 4 | Status: COMPLETED